Share this article on:

Bladder cancer

Morgan, Todd M; Clark, Peter E

doi: 10.1097/CCO.0b013e3283378c6b
Genitourinary system: Edited by Arif Hussain

Purpose of review To review the diagnosis and management of all stages of bladder cancer with an emphasis on studies and developments within the last year.

Recent findings Cystoscopy remains the gold standard for diagnosis of bladder tumors, though fluorescent light and urinary biomarkers can both improve the sensitivity of cancer detection. Management of high-risk patients with nonmuscle invasive cancer continues to be controversial, with a number of risk assessment tools developed to help stratify patients to cystectomy or bladder-sparing regimens. Intravesical therapy is utilized both as a one-time perioperative regimen and as a weekly regimen, and research continues in the development of agents for bacillus Calmette-Guerin-refractory superficial bladder cancer. In patients undergoing cystectomy, evidence supports the need for an adequate lymphadenectomy. Although there are limited data on robotic assisted radical cystectomy, initial reports suggest that an appropriate lymph node dissection can be performed. The role of bladder-sparing modalities as well as the use of adjuvant and neoadjuvant therapies is still debated. Trials investigating these therapies continue to seek to improve both oncologic outcomes and quality of life for patients with invasive bladder cancer.

Summary Progress continues in bladder cancer diagnosis and management, and we anticipate that future work will further advance the care of patients with this disease.

Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA

Correspondence to Peter E. Clark, MD, Vanderbilt University Medical Center, A-1302 Medical Center North, Nashville, TN 37232-2765, USA E-mail:

Back to Top | Article Outline


There were estimated to be approximately 70 980 new cases of bladder cancer and 14 330 deaths from bladder cancer in the United States in 2009 [1]. Although population-adjusted incidence rates have remained stable the past 35 years, bladder cancer remains the fifth leading new cancer diagnosis in the United States and is fourth among men. This article will review the diagnosis and management of bladder cancer, emphasizing developments over the past year.

Back to Top | Article Outline


Direct cystoscopic visualization of the bladder continues to be the gold standard in patients with microscopic or gross hematuria. Although increasing evidence supports the greater sensitivity of fluorescence cystoscopy for detection of bladder tumors, it remains to be seen whether this will translate into decreased progression rates and improved overall survival [2,3]. Newer technologies under development may improve the precision of identifying bladder tumors while also providing real-time pathologic information. For example, optical coherence tomography (OCT) allows cross-sectional imaging of bladder tissue using a small probe and may both identify bladder tumors and determine their depth of invasion [4]. When coupled to fluorescence cystoscopy, OCT demonstrated a sensitivity of 97.5% and a specificity of 97.9% for the identification of malignant bladder lesions [5•]. Confocal laser endomicroscopy is another interesting technology under investigation. Using a 2.6 mm probe, cellular architecture can be assessed with successful differentiation between normal urothelium, low-grade tumors, and high-grade tumors [6•].

Significant research continues to focus on the development and implementation of urinary biomarkers for both diagnosis and surveillance. Although six tests currently have the Food and Drug Administration (FDA) approval, many more are under investigation [7]. The most effective current application is in the surveillance of patients with a history of bladder carcinoma. Nuclear matrix protein-22 (NMP22), for example, has consistently demonstrated significantly greater sensitivity than cytology in predicting recurrence in patients with a history of bladder cancer [8]. Additionally, although NMP22 performs better than cytology in the diagnosis of bladder cancer [9], a recent trial of NMP22 in a cohort of asymptomatic patients demonstrated a low positive predictive value likely related to the very low cancer prevalence in this population [10]. UroVysion (Abott Molecular Inc., Des Plaines, Illinois, USA) is a fluorescence in-situ hybridization assay that also consistently outperforms cytology with respect to sensitivity, though at significantly greater cost [11]. Additionally, it may be used in patients who have undergone intravesical therapy [12,13]. Other recent studies have evaluated panels of genes [14,15], urinary microsatellite analysis [16], and chromosomal instability [17] as potential markers of bladder cancer recurrence and progression. Finally, urinary proteomics has recently shown promise, with urinary cystatin B being one example of an investigational protein identified through proteomic profiling that appears to be an independent predictor of both recurrence and progression [18,19].

Back to Top | Article Outline

Management of nonmuscle-invasive bladder cancer

Although up to 80% of bladder cancers are nonmuscle invasive (NMIBC) at the time of diagnosis, 15–25% will eventually progress to invasive disease. Complete transurethral resection of the tumor with close cystoscopic surveillance remains the standard of care [20]. Although many different surveillance protocols are employed, Hollenbeck et al.[21•] demonstrated that increasing use of surveillance and treatment in patients with early-stage bladder cancer does not necessarily improve outcomes. In their SEER-Medicare cohort, expenditures for providers with greatest use of resources were over two-fold that of the lowest expenditure quartile, yet mortality was not improved. When recurrent tumors are detected by cystoscopic surveillance, options include endoscopic resection with possible intravesical chemotherapy vs. a more aggressive intervention such as radical cystectomy.

Level I evidence supports a single, prophylactic postoperative instillation of intravesical chemotherapy in patients with NMIBC [22]. This is based on a 39% decrease in the odds of tumor recurrence and is reflected in the published guidelines [20,23•]. It is important to note that immediate intravesical therapy postresection should be held if there is concern for bladder perforation. Interestingly, a recent study brings the effectiveness of perioperative therapy into question. Gudjonsson et al.[24•] randomized 305 patients to receive either postoperative epirubicin or resection alone. Although a significant decrease in recurrence was seen in the epirubicin group as a whole (hazard ratio 0.56, P = 0.002), this effect was limited to patients with primary or solitary tumors. No benefit was observed for those with intermediate or high-risk NMIBC.

Despite improvements in intravesical therapy, patients with T1 disease opting to pursue bladder-sparing therapy rather than radical cystectomy present a substantial challenge. These patients carry a high risk of recurrence and progression, and there are not yet clear criteria delineating which patients should undergo aggressive surgical management. Current standard of care mandates complete transurethral resection of these tumors and inclusion of the muscularis propria in the tumor specimen. Understaging of T1 lesions without the presence of muscularis propria has been well documented and may be as high as 62% [25]. Re-resection is required in the absence of muscle in the biopsy specimen, and some have advocated a second resection of all newly diagnosed T1 lesions to decrease the risk of understaging [26]. Furthermore, though radical cystectomy overtreats a significant percentage of these patients, the survival benefit has been repeatedly documented. A recent study reported 10-year cancer-specific survival of 78.7% in a large nonrandomized cohort undergoing early cystectomy and 64.5% in those undergoing delayed cystectomy [27].

In order to stratify patients to cystectomy vs. bladder-sparing regimens, a number of predictors have been identified. The presence of carcinoma in situ (CIS) or muscularis mucosa invasion has been consistently associated with upstaging at cystectomy [28–31]. Other important predictors of understaging and disease progression include lymphovascular invasion, variant histology such as small-cell or micropapillary components, and urethral involvement [31–33]. Although assessment of these factors can help guide treatment direction, additional tools to help differentiate those at high risk of progression from those unlikely to progress are needed. An increasing number of risk assessment tools have been developed; however, none have been sufficiently validated to justify routine use [31–35].

Back to Top | Article Outline

Intravesical therapy

There are a number of additional evidence-based principles of intravesical therapy for NMIBC that form the foundation for treating these patients. A recent individual patient data meta-analysis confirmed the superiority of bacillus Calmette-Guerin (BCG) to mitomycin C (MMC) in the treatment of NMIBC, but only with inclusion of a maintenance regimen [36••]. CIS, in particular, responds well to BCG treatment, with a complete response rate of up to 68% [37]. Additionally, patients suffering a recurrence after one induction course of BCG may respond to another induction and/or maintenance course of BCG. Continued disease after this, however, signals unlikely benefit from additional BCG.

Significant research continues to be devoted to improving the efficacy of intravesical therapy. Administration of MMC via microwave hyperthermia [38] or electromotive drug administration [39] has shown benefit over MMC alone. A derivative of MMC, apaziquone, has also demonstrated potential as an intravesical agent and has recently been given FDA fast-track status for approval in NMIBC [40,41]. In patients with BCG-refractory CIS, valrubicin remains the only FDA-approved drug and is again available [42]. Other promising agents include mycobacterial cell wall-DNA complex, with response rates up to 46% in a mostly pretreated population [43], and DTA-H19, a DNA plasmid carrying the diphtheria toxin A gene [44]. Both of these therapies are now in clinical trials.

Back to Top | Article Outline

Management of muscle-invasive bladder cancer

The standard therapy for muscle-invasive bladder cancer is radical cystoprostatectomy in men and anterior pelvic exenteration in women. Overall survival after cystectomy is closely related to pathologic tumor stage. In patients without lymph node involvement, Stein et al.[45] reported 10-year recurrence-free survival rates of 87% in T2, 76% in T3, and 45% in T4 disease. Lymph node involvement varied with tumor stage, ranging from 18% of patients with T2a disease to 45% of patients with T3/T4 disease, and the 10-year recurrence-free survival rate in these patients was 34%. Urethral recurrence after cystectomy is rare, and urethrectomy is only necessary in the setting of a positive urethral margin on intraoperative frozen section or when there is cancer invading the prostatic stroma in men. A follow-up report from the University of Southern California demonstrated that orthotopic diversion following radical cystectomy does not compromise oncologic outcomes in women [46]. Recurrence-free survival at 10 years was 55%, with a low rate of pelvic or urethral recurrence (2.5%).

Recent large single-institution studies have confirmed the significant risks associated with cystectomy. In a single-center series of over 1100 radical cystectomy patients, the 90-day complication rate was 64%, with 13% graded as significant [47•]. Gastrointestinal complications were most common, followed by infectious and wound complications. Another single-institution series of 538 patients reported a 45% 30-day complication rate, with 7.4% classified as major [48]. Increasing data support the need to perform cystectomies at high-volume centers. An evaluation of the complication rates at over 100 centers demonstrated significant differences in perioperative mortality depending on the number of cystectomies performed each year [49]. Rates ranged from nearly 4% at centers performing fewer than three cystectomies annually to 1% at centers performing over 50 each year.

Two key surgical factors that have a significant impact on oncologic outcome are surgical margin status and the extent of lymphadenectomy. Dotan et al. [50] reported a positive surgical margin rate of 4.2% in their series of 1589 radical cystectomies. Patients with positive margins had a local recurrence rate of 21% at 5 years, compared with 6% in patients with negative surgical margins. The hazard ratio for disease-specific death in this and other studies has ranged from 2 to 2.7 in patients with positive margins [50,51]. The relationship between lymph node counts and survival after cystectomy has been repeatedly demonstrated. Herr [52] showed significant differences in survival among 68 node-positive patients depending on the number of lymph nodes removed. Additionally, among 258 node-negative patients, the number of lymph nodes removed remained an important predictor of survival. Another recent population-based study demonstrated an independent association between increasing lymph node counts and improved overall survival after cystectomy [53].

Lymph node density (LND) – the percentage of positive lymph nodes relative to the total number of lymph nodes removed – remains an important predictor of oncologic outcome. Among 248 node-positive patients treated at two high-volume cancer centers, patients with LND more than 20% were found to have an independent 2.75-fold greater risk of disease-specific death vs. those with LND less than 20% [54]. Bruins et al.[55] found that even in patients with only 1–2 positive lymph nodes, LND is a significant predictor of survival at a density cut-off of 4%. Although these studies and others confirm the importance of obtaining a sufficient lymph node yield at surgery, still unknown is whether the benefit is solely one of staging accuracy or whether there is a therapeutic benefit from removal of nodal metastases. Surprisingly, 16% of patients in the SEER registry who underwent radical cystectomy in 2004 did not undergo lymphadenectomy, though this figure has decreased by over half since 1988 [56].

The importance of performing a satisfactory pelvic lymphadenectomy has become particularly relevant in light of the increasing use of minimally invasive approaches to radical cystectomy. Although a number of studies have evaluated the safety of laparoscopic and robotic assisted radical cystectomy, there is little data to date on either the adequacy of lymphadenectomy or oncologic outcomes. As expected, minimally invasive approaches appear to result in a decreased blood loss and transfusion requirement as well as shorter hospital stays [57–60]. In addition, Ng et al.[61•] have reported a significantly lower overall (41 vs. 59%) and major (17 vs. 31%) complication rate in their nonrandomized cohort of patients undergoing robotic vs. open radical cystectomy. Average lymph node counts have been reported in the range of 16–19; however, not all series have performed dissections within at least the standard boundaries [58,62]. Positive surgical margin rates have been appropriately low – zero in some small series and 7% in a larger series, which also reported a 9% positive margin rate in their open cohort [58,59,61•]. One review of data from 48 papers on laparoscopic and robotic cystectomies suggested that minimally invasive approaches can achieve comparable results to open surgery both in terms of the extent of lymphadenectomy and intermediate-term oncological outcomes [63]. Further follow-up will be needed to assess the true oncologic efficacy of robotic cystectomy.

Another trend has been the increased use of prostate-sparing techniques, performed with the idea of increasing continence and potency [64–66]. Rozet et al.[67] describe utilizing transurethral resection of the prostate with frozen sections sent to exclude any prostatic urothelial carcinoma prior to bladder removal. They report high potency and continence rates as well as a 5-year overall survival rate of 67%. Significant questions remain, however, as to whether this is an appropriate approach from an oncologic perspective [68]. Prostate adenocarcinoma has been identified in up to 48% of radical cystoprostatectomy specimens, with clinically significant features present in 35–48% of these patients with prostate cancer [69,70]. Prostatic urothelial carcinoma has also been identified in up to 48% of cystoprostatectomy specimens [70]. Given the success of nerve-sparing techniques for preservation of erectile function in appropriate patients [71], the role of prostate-sparing cystectomy is limited.

As an alternative to radical cystectomy, a number of bladder-sparing regimens have been investigated. These consist of some combination of endoscopic resection, chemotherapy, and radiation. No randomized trials have compared these regimens with radical cystectomy; however, some series have demonstrated survival rates within the range of what would be expected with surgery. Rodel et al.[72] reported a 10-year disease-specific survival of 42% with over 80% of survivors preserving their bladder. A more recent study evaluated 63 patients with muscle-invasive cancer who had a complete response to neoadjuvant chemotherapy and subsequently refused cystectomy [73]. At a median follow-up of over 7 years, overall survival was 64% with 54% preserving their bladder. Solsona et al. [74•] allowed 146 patients with microscopic residual muscle-invasive cancer to choose between radical cystectomy and cisplatin-based chemotherapy. There was no difference in cancer-specific survival between the two groups; however, of 51 responders in the bladder preservation group, five (10%) died after initial local recurrence [75].

Chemoradiation is likely more effective than chemotherapy alone, and one recent study showed excellent results with gemcitabine and radiation, reporting a 5-year disease-specific survival of 82% [76]. Additionally, late pelvic toxicity may be lower than previously thought. A review of four RTOG studies found that only 7% of patients had significant late pelvic toxicity and nearly all resolved [77•]. Candidates for bladder-preserving protocols generally are recommended to have a solitary tumor less than 5 cm in size, clinical stage T2, no hydronephrosis, and no evidence of lymphatic or distant metastases.

Back to Top | Article Outline

Neoadjuvant and adjuvant chemotherapy

The administration of chemotherapy before or after radical cystectomy continues to be an area of significant interest and investigation. Neoadjuvant chemotherapy offers a number of theoretical and real advantages, including early treatment of microscopic metastases, downstaging of the primary tumor, and improved patient tolerance relative to adjuvant chemotherapy. A potential disadvantage, however, is the delay in cystectomy, as recent population-based studies have confirmed prior institutional series demonstrating worse outcome for patients with longer waiting periods between transurethral resection and cystectomy [78–80].

Currently, there is greater evidence supporting the use of neoadjuvant chemotherapy than there is in favor of adjuvant chemotherapy [81]. In what remains one of the pivotal neoadjuvant trials, SWOG 8710 randomized 307 patients with locally advanced bladder cancer to cystectomy with or without neoadjuvant chemotherapy [82]. Patients randomized to the chemotherapy group received methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) and had significantly improved overall and disease-specific survival (hazard ratio 0.75 and 0.60, respectively). The greatest benefit was to patients with T3 or T4 disease, whereas there appeared to be little impact on patients with T2 cancer. Notably, the survival benefit was largely linked to tumor downstaging, with pT0 rates of 38% in the MVAC group and 15% in the cystectomy-only group. A meta-analysis of 3005 patients from 11 randomized trials found that neoadjuvant chemotherapy provided a 5% absolute overall survival benefit at 5 years (P = 0.003) [83]. To date, however, neoadjuvant chemotherapy is infrequently utilized even among patients with stage 3 or 4 disease [84].

In contrast to neoadjuvant chemotherapy, the data supporting the use of adjuvant chemotherapy are much less robust. Potential benefits of adjuvant therapy include the selection of patients at highest risk for failure and the ability to perform surgery without delay. However, most adjuvant chemotherapy trials have shown no benefit [81]. Although a large meta-analysis found a statistically significant 9% improvement in survival at 3 years, the included studies had a number of methodological flaws such as poor accrual over long periods of time [85]. Whether or not the neoadjuvant data can be extrapolated to the adjuvant setting remains an area of great interest and debate, with at least one study showing equivalent results [86]. In patients with persistent node-positive disease at cystectomy despite neoadjuvant treatment, Kassouf et al. [87] found a significant improvement in recurrence-free survival with the administration of adjuvant chemotherapy (13 vs. 5 months, P = 0.02).

Back to Top | Article Outline

Metastatic disease

The importance of a multidrug, cisplatin-based regimen in the treatment of advanced urothelial carcinoma has been well documented. MVAC has generally been the gold standard for metastatic bladder cancer since the report by Loehrer et al.[88] demonstrating a significant survival benefit compared to cisplatin monotherapy. However, this study also confirmed the substantial toxicity of MVAC that carries an approximately 4% toxic death rate. As a result of a better safety profile and apparent noninferior efficacy, gemcitabine with cisplatin has become an acceptable alternative and, in many ways, the community gold standard in both the metastatic and the neoadjuvant settings [89]. In a phase III trial of 405 patients with advanced disease randomized to MVAC vs. gemcitabine with cisplatin, there was no difference in overall or progression-free survival between the two study arms [90]. This was not a formal equivalence trial, however, and it is unlikely that one will be performed.

Outcomes for patients with advanced bladder cancer continue to be poor despite these advances in chemotherapy, and successful new drug combinations and novel agents are needed. In a phase III trial, Sternberg et al.[91] randomized patients with advanced tumors to standard MVAC vs. a high-dose intensity MVAC regimen. Although toxicities remained relatively similar, patients in the high-dose regimen had significantly improved overall survival (hazard ratio = 0.73). Another regimen recently evaluated was sequential administration of doxorubicin and gemcitabine followed by ifosfamide, paclitaxel, and cisplatin [92]. The median overall survival of 16 months was comparable to studies of MVAC and gemcitabine with cisplatin; however, 68% of patients experienced grade 3–4 neutropenia. Whether these investigations translate into a broader standardization of regimens remains to be seen. Surprisingly, Porter et al.[84] found gemcitabine, carboplatin, and paclitaxel to be the most commonly utilized chemotherapies in a 2003 SEER-Medicare cohort.

Nonplatinum-containing regimens remain an area of ongoing investigation. Calabro et al.[93] evaluated the administration of gemcitabine and paclitaxel in patients with advanced bladder cancer, reporting a median survival of 13 months. The authors suggest that this may be a potential treatment option for patients unable to receive cisplatin due to poor performance status or renal impairment. Additionally, there continues to be significant interest in targeted, molecular pathway-based therapies. Phase II trials of the tyrosine kinase inhibitors sorafenib and lapatinib as second-line therapies were both recently published [94,95]. Neither drug showed significant activity in this population, with median time to disease progression of approximately 2 months in each trial. The alkylating agent vinflunine has recently been evaluated in patients previously treated with a platinum-based regimen, resulting in a median progression-free survival of 2.8 months and again demonstrating the difficulty in slowing the disease course in these individuals [96].

Back to Top | Article Outline


Significant progress continues to be made in bladder cancer. The past year has seen increasing evidence to support the use of urinary biomarkers as well as further development of technologies to assist with cystoscopic identification of tumors. There is continued debate over how best to manage patients with T1 cancer; hopefully, newer intravesical therapies in BCG-refractory disease will help decrease the need for cystectomy in these and other high-risk NMIBC patients. In those undergoing cystectomy, substantial evidence supports the need for an adequate lymphadenectomy, and initial data regarding the robotic approach suggest that comparable lymph node counts are feasible in experienced hands. Finally, the role of bladder-sparing modalities as well as the use of adjuvant and neoadjuvant therapies continues to evolve, and further trials investigating these therapies will hopefully improve both oncologic outcomes and quality of life for patients with invasive bladder cancer.

Back to Top | Article Outline

References and recommended reading

Papers of particular interest, published within the annual period of review, have been highlighted as:

• of special interest

•• of outstanding interest

Additional references related to this topic can also be found in the Current World Literature section in this issue (p. 298).

1 Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225–249.
2 Denzinger S, Wieland WF, Otto W, et al. Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study. BJU Int 2008; 101:566–569.
3 Grossman HB, Gomella L, Fradet Y, et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 2007; 178:62–67.
4 Goh AC, Tresser NJ, Shen SS, et al. Optical coherence tomography as an adjunct to white light cystoscopy for intravesical real-time imaging and staging of bladder cancer. Urology 2008; 72:133–137.
5• Schmidbauer J, Remzi M, Klatte T, et al. Fluorescence cystoscopy with high-resolution optical coherence tomography imaging as an adjunct reduces false-positive findings in the diagnosis of urothelial carcinoma of the bladder. Eur Urol 2009; 56:914–919. This study describes OCT, a modality that provides real-time tumor staging information, differentiating CIS, Ta, T1, and T2 lesions at the time of cystoscopy. OCT also improved the specificity of fluorescence cystoscopy in diagnosing urothelial carcinoma.
6• Sonn GA, Jones S-NE, Tarin TV, et al. Optical biopsy of human bladder neoplasia with in vivo confocal laser endomicroscopy. J Urol 2009; 182:1299–1305. Confocal laser endomicroscopy can provide histologic information during cystoscopic evaluation of the bladder. In this pilot study, confocal laser endomicroscopy successfully differentiated normal vs. cancerous urothelium and low-grade vs. high-grade tumors.
7 Chade DC, Shariat S, Godoy G, et al. Critical review of biomarkers for the early detection and surveillance of bladder cancer. J Men Health 2009; 6:368–382.
8 Gupta NP, Sharma N, Kumar R. Nuclear matrix protein 22 as adjunct to urine cytology and cystoscopy in follow-up of superficial TCC of urinary bladder. Urology 2009; 73:592–596, discussion 596–597.
9 Lotan Y, Capitanio U, Shariat SF, et al. Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection. BJU Int 2009; 103:1368–1374.
10 Lotan Y, Elias K, Svatek RS, et al. Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker. J Urol 2009; 182:52–57, discussion 58.
11 Hajdinjak T. UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol 2008; 26:646–651.
12 Savic S, Zlobec I, Thalmann GN, et al. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical bacillus Calmette-Guérin therapy. Int J Cancer 2009; 124:2899–2904.
13 Whitson J, Berry A, Carroll P, et al. A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy. BJU Int 2009; 104:336–339.
14 Mitra AP, Pagliarulo V, Yang D, et al. Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J Clin Oncol 2009; 27:3929–3937.
15 Wang R, Morris DS, Tomlins SA, et al. Development of a multiplex quantitative PCR signature to predict progression in nonmuscle-invasive bladder cancer. Cancer Res 2009; 69:3810–3818.
16 de Bekker-Grob EW, van der Aa MNM, Zwarthoff EC, et al. Nonmuscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative? BJU Int 2009; 104:41–47.
17 Zieger K, Wiuf C, Jensen KM, et al. Chromosomal imbalance in the progression of high-risk nonmuscle invasive bladder cancer. BMC Cancer 2009; 9:149.
18 Feldman AS, Banyard J, Wu C-L, et al. Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression. Clin Cancer Res 2009; 15:1024–1031.
19 Schiffer E, Vlahou A, Petrolekas A, et al. Prediction of muscle-invasive bladder cancer using urinary proteomics. Clin Cancer Res 2009; 15:4935–4943.
20 Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007; 178:2314–2330.
21• Hollenbeck BK, Ye Z, Dunn RL, et al. Provider treatment intensity and outcomes for patients with early-stage bladder cancer. J Natl Cancer Inst 2009; 101:571–580. This SEER review evaluated the average expenditures on early-stage bladder cancer patients by different providers and assessed whether there was any improvement in cancer outcomes based on increased treatment intensity. Although patients treated by high-intensity providers were more likely to undergo major medical interventions, no survival benefit was observed with increasing treatment intensity.
22 Sylvester RJ, Oosterlinck W, van der Meijden APM. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004; 171:2186–2190, quiz 2435.
23• Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on nonmuscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008; 54:303–314. This review provides an excellent summary of the current standards of care and management options in patients with high-risk NMIBC.
24• Gudjonsson S, Adell L, Merdasa F, et al. Should all patients with nonmuscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol 2009; 55:773–780. This is a prospective, randomized trial of a single perioperative intravesical instillation of epirubicin to prevent recurrence of NMIBC. Although use of perioperative chemotherapy provided a significant reduction in recurrence rates, the benefit was primarily seen in low-risk patients.
25 Dutta SC, Smith JA, Shappell SB, et al. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 2001; 166:490–493.
26 Kulkarni G, Hakenberg O, Gschwend J, et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol 2010; 57:60–70.
27 Hautmann RE, Volkmer BG, Gust K. Quantification of the survival benefit of early versus deferred cystectomy in high-risk nonmuscle invasive bladder cancer (T1 G3). World J Urol 2009; 27:347–351.
28 Holmäng S, Hedelin H, Anderström C, et al. The importance of the depth of invasion in stage T1 bladder carcinoma: a prospective cohort study. J Urol 1997; 157:800–803, discussion 804.
29 Masood S, Sriprasad S, Palmer JH, et al. T1G3 bladder cancer: indications for early cystectomy. Int Urol Nephrol 2004; 36:41–44.
30 Orsola A, Trias I, Raventós CX, et al. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-nontreated patients. Eur Urol 2005; 48:231–238, discussion 238.
31 Weizer AZ, Wasco MJ, Wang R, et al. Multiple adverse histological features increase the odds of under staging T1 bladder cancer. J Urol 2009; 182:59–65, discussion 65.
32 Andius P, Johansson SL, Holmäng S. Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion. Urology 2007; 70:758–762.
33 Cho K, Seo H, Joung J, et al. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer. J Urol 2009; 182:2625–2631.
34 Shariat SF, Margulis V, Lotan Y, et al. Nomograms for bladder cancer. Eur Urol 2008; 54:41–53.
35 Sylvester RJ, van der Meijden APM, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49:466–477.
36•• Malmström P-U, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for nonmuscle-invasive bladder cancer. Eur Urol 2009; 56:247–256. This well executed meta-analysis of BCG vs. MMC for NMIBC confirms the importance of BCG maintenance in preventing tumor recurrence. When maintenance BCG was used, it demonstrated superiority to MMC. Importantly, no statistically significant differences were observed for progression or survival between the BCG and MMC groups.
37 Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol 2000; 163:1124–1129.
38 Witjes AJ, Hendricksen K, Gofrit O, et al. Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party. World J Urol 2009; 27:319–324.
39 Di Stasi SM, Riedl C. Updates in intravesical electromotive drug administration of mitomycin-C for nonmuscle invasive bladder cancer. World J Urol 2009; 27:325–330.
40 Jain A, Phillips RM, Scally AJ, et al. Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates. Urology 2009; 73:1083–1086.
41 van der Heijden AG, Moonen PM, Cornel EB, et al. Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. J Urol 2006; 176:1349–1353, discussion 1353.
42 Steinberg G, Bahnson R, Brosman S, et al. Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 2000; 163:761–767.
43 Morales A, Phadke K, Steinhoff G. Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed. J Urol 2009; 181:1040–1045.
44 Sidi AA, Ohana P, Benjamin S, et al. Phase I/II marker lesion study of intravesical BC-819 DNA plasmid in H19 over expressing superficial bladder cancer refractory to bacillus Calmette-Guerin. J Urol 2008; 180:2379–2383.
45 Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19:666–675.
46 Stein JP, Penson DF, Lee C, et al. Long-term oncological outcomes in women undergoing radical cystectomy and orthotopic diversion for bladder cancer. J Urol 2009; 181:2052–2058, discussion 2058–2059.
47• Shabsigh A, Korets R, Vora KC, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol 2009; 55:164–176. This paper takes a significant step toward improving the standardization of morbidity reporting following major urologic surgery. Complications within 90 days of radical cystectomy were reported using a modified Clavien grading system, and this stringent reporting resulted in a potentially more realistic description of postoperative complications.
48 Lowrance WT, Rumohr JA, Chang SS, et al. Contemporary open radical cystectomy: analysis of perioperative outcomes. J Urol 2008; 179:1313–1318, discussion 1318.
49 Barbieri CE, Lee B, Cookson MS, et al. Association of procedure volume with radical cystectomy outcomes in a nationwide database. J Urol 2007; 178:1418–1421, discussion 1421–1412.
50 Dotan ZA, Kavanagh K, Yossepowitch O, et al. Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival. J Urol 2007; 178:2308–2312, discussion 2313.
51 Herr HW, Faulkner JR, Grossman HB, et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol 2004; 22:2781–2789.
52 Herr HW. Superiority of ratio based lymph node staging for bladder cancer. J Urol 2003; 169:943–945.
53 Wright JL, Lin DW, Porter MP. The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy. Cancer 2008; 112:2401–2408.
54 Kassouf W, Agarwal PK, Herr HW, et al. Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. J Clin Oncol 2008; 26:121–126.
55 Bruins HM, Huang GJ, Cai J, et al. Clinical outcomes and recurrence predictors of lymph node positive urothelial cancer after cystectomy. J Urol 2009; 182:2182–2187.
56 Hellenthal NJ, Ramirez ML, Evans CP, et al. Trends in pelvic lymphadenectomy at the time of radical cystectomy: 1988 to 2004. J Urol 2009; 181:2490–2495.
57 Guillotreau J, Gamé X, Mouzin M, et al. Radical cystectomy for bladder cancer: morbidity of laparoscopic versus open surgery. J Urol 2009; 181:554–559, discussion 559.
58 Murphy DG, Challacombe BJ, Elhage O, et al. Robotic-assisted laparoscopic radical cystectomy with extracorporeal urinary diversion: initial experience. Eur Urol 2008; 54:570–580.
59 Pruthi RS, Wallen EM. Robotic-assisted laparoscopic radical cystoprostatectomy. Eur Urol 2008; 53:310–322.
60 Wang G, Barocas D, Raman J, et al. Robotic vs open radical cystectomy: prospective comparison of perioperative outcomes and pathological measures of early oncological efficacy. BJU Int 2008; 101:89–93.
61• Ng C, Kauffman E, Lee M, et al. A comparison of postoperative complications in open versus robotic cystectomy. Eur Urol 2010; 57:274–282. This report compared 83 patients who underwent robotic cystectomy to 104 patients who had open cystectomy. Although there are clear potential confounders, the robotic group had a lower complication rate as well as a significant decrease in blood loss.
62 Pruthi RS, Smith A, Wallen EM. Evaluating the learning curve for robot-assisted laparoscopic radical cystectomy. J Endourol 2008; 22:2469–2474.
63 Haber G-P, Crouzet S, Gill IS. Laparoscopic and robotic assisted radical cystectomy for bladder cancer: a critical analysis. Eur Urol 2008; 54:54–62.
64 Botto H, Sebe P, Molinie V, et al. Prostatic capsule- and seminal-sparing cystectomy for bladder carcinoma: initial results for selected patients. BJU Int 2004; 94:1021–1025.
65 Muto G, Bardari F, D’Urso L, et al. Seminal sparing cystectomy and ileocapsuloplasty: long-term followup results. J Urol 2004; 172:76–80.
66 Vallancien G, Abou El Fettouh H, Cathelineau X, et al. Cystectomy with prostate sparing for bladder cancer in 100 patients: 10-year experience. J Urol 2002; 168:2413–2417.
67 Rozet F, Lesur G, Cathelineau X, et al. Oncological evaluation of prostate sparing cystectomy: the Montsouris long-term results. J Urol 2008; 179:2170–2174, discussion 2174–2175.
68 Stein JP, Hautmann RE, Penson D, et al. Prostate-sparing cystectomy: a review of the oncologic and functional outcomes. Contraindicated in patients with bladder cancer. Urol Oncol 2009; 27:466–472.
69 Pettus J, Al-Ahmadie H, Barocas D, et al. Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy. Eur Urol 2008; 53:370–375.
70 Revelo MP, Cookson MS, Chang SS, et al. Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies: implications for possible apical sparing surgery. J Urol 2004; 171:646–651.
71 Hekal IA, El-Bahnasawy MS, Mosbah A, et al. Recoverability of erectile function in postradical cystectomy patients: subjective and objective evaluations. Eur Urol 2009; 55:275–283.
72 Rodel C, Grabenbauer GG, Kühn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002; 20:3061–3071.
73 Herr HW. Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 2008; 54:126–132.
74• Solsona E, Climent MA, Iborra I, et al. Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy. Eur Urol 2009; 55:911–919. This is an interesting study of patients with muscle-invasive cancer treated initially with TURBT and systemic chemotherapy. Although not randomized, patients who opted for the bladder-sparing regimen had similar survival rates as those opting for up front cystectomy.
75 Herr HW. Editorial comment on: Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy. Eur Urol 2009; 55:920–921.
76 Oh KS, Soto DE, Smith DC, et al. Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial. Int J Radiat Oncol Biol Phys 2009; 74:511–517.
77• Efstathiou JA, Bae K, Shipley WU, et al. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol 2009; 27:4055–4061. This study reports on the long-term effects of combined chemotherapy and radiation on 285 patients from four RTOG studies. Late significant genitourinary and gastrointestinal toxicities were rare, supporting use of chemoradiotherapy in select patients with bladder cancer.
78 Chang SS, Hassan JM, Cookson MS, et al. Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. J Urol 2003; 170:1085–1087.
79 Gore JL, Lai J, Setodji CM, et al. Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis. Cancer 2009; 115:988–996.
80 Kulkarni GS, Urbach DR, Austin PC, et al. Longer wait times increase overall mortality in patients with bladder cancer. J Urol 2009; 182:1318–1324.
81 Calabrò F, Sternberg CN. Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer. Eur Urol 2009; 55:348–358.
82 Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349:859–866.
83 Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005; 48:202–205.
84 Porter M, Kerrigan M, Donato B, et al. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urol Oncol 2010 [Epub ahead of print].
85 Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol 2005; 48:189–199.
86 Millikan R, Dinney C, Swanson D, et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 2001; 19:4005–4013.
87 Kassouf W, Agarwal PK, Grossman HB, et al. Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. Urology 2009; 73:147–152.
88 Loehrer PJ, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992; 10:1066–1073.
89 Dash A, Pettus JA, Herr HW, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer 2008; 113:2471–2477.
90 von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23:4602–4608.
91 Sternberg CN, de Mulder P, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006; 42:50–54.
92 Milowsky MI, Nanus DM, Maluf FC, et al. Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. J Clin Oncol 2009; 27:4062–4067.
93 Calabro F, Lorusso V, Rosati G, et al. Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. Cancer 2009; 115:2652–2659.
94 Dreicer R, Li H, Stein M, et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer 2009; 115:4090–4095.
95 Wülfing C, Machiels J-PH, Richel DJ, et al. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 2009; 115:2881–2890.
96 Vaughn DJ, Srinivas S, Stadler WM, et al. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer 2009; 115:4110–4117.

bladder cancer; diagnosis; review; treatment

© 2010 Lippincott Williams & Wilkins, Inc.